Business Wire

ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud

24.9.2026 14:30:00 CEST | Business Wire | Press release

Share

ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia.

ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform.

Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes.

The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's leading financial institutions, government agencies and Fortune 500 companies.

ParaScript’s technology integrates into Stakk’s SaaS platform, Digital Persona Graph, combining AI-powered document processing and recognition capabilities with identity, behavioral and contextual data to provide a more complete view of each digital interaction. This enables organizations to better identify AI-driven digital identity fraud and make explainable decisions in milliseconds.

The combined platform can support a broader range of workflows across regulated industries and jurisdictions, while its increased scale creates a continuously expanding intelligence base of emerging fraud signals. This gives customers greater visibility into evolving threats and strengthens their ability to detect and prevent fraud as new patterns emerge.

Emiliano Giacchetti has been appointed Chief Executive Officer of Stakk IQ and ParaScript. Pending shareholder approval at the upcoming Annual General Meeting, he is expected to assume the role of Group Chief Executive Officer of Stakk Limited, giving him responsibility for the strategy, operations and financial performance of Stakk Limited and its subsidiaries.

“Stakk and ParaScript have come together around a clear and urgent global requirement: helping highly regulated organizations properly vet digital interactions, identities and documents,” said Giacchetti. “The combined group has the technology, intelligence, enterprise relationships and international reach required to address that challenge at scale. It also has a substantial contracted revenue base and a clear pathway to deliver the financial commitments made to shareholders.”

Stakk board member Arthur Lo added, “The completion of this acquisition establishes Stakk as an international digital trust platform at a time when the need for stronger AI-based fraud solutions has never been greater. As generative AI, synthetic identities, deepfakes and document manipulation continue to proliferate, this deal closes the gap needed to address one of the world’s fastest growing markets.”

About ParaScript

ParaScript develops AI-powered recognition solutions that process over 100 billion documents annually, touching nearly everyone in the U.S. and people in more than 15 countries worldwide whenever they send mail, write checks or interact with financial institutions and government agencies. Leading corporations in the U.S., Europe, Latin America and Australia rely on ParaScript to automate their document processing, improving efficiency and accuracy, while reducing costs. Visit parascript.com to learn more.

About Stakk

Stakk Limited (ASX: SKK) is a scaled, profitable and globally relevant AI-native digital trust infrastructure group focused on combating fraud. Its integrated platform enables financial institutions, governments, law-enforcement agencies, healthcare providers, insurers, telecommunications companies, and other regulated enterprises to establish trust across the complete interaction – from identity verification and document authentication through to fraud prevention, transaction authorization, and real-time contextual decisioning.

Stakk combines more than 30 years of proprietary AI-powered document intelligence with contextual Digital Personas, federated signal intelligence and pre-execution decisioning. The group serves more than 300 enterprise customers across the United States, Europe, the Middle East and Australia and processes more than 110 billion interactions annually, creating a continuously expanding intelligence asset that strengthens its ability to identify and respond to evolving AI-driven fraud threats.

For more information visit stakk.tech.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260924529627/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release

Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa

SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release

Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as

Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release

Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release

-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s

Arthur D. Little GEMRIX 2026 Report: The EV TRANSITION is Now an Ecosystem Race, With China Setting the Global Pace24.9.2026 12:15:00 CEST | Press release

Ecosystem, not vehicle technology is now decisive in electric vehicle (EV) adoption, and is responsible for sharp differences between markets. This is the key finding of Arthur D. Little (ADL)'s 2026 Global Electric Mobility Readiness Index (GEMRIX), which shows where ecosystems are ready and where structural gaps hold EVs back. China and Norway have both passed the point where EVs have achieved parity with internal combustion engine (ICE) vehicles. The most comprehensive study of its kind, the third edition of GEMRIX assesses 31 markets across five dimensions: macro factors, EV market/competition, customer readiness, public charging infrastructure, total cost of ownership and regulation. A score of 100 indicates broad market-readiness parity between EVs and ICE vehicles. The study highlights three global conclusions: A small group has pulled ahead. China (106) and Norway (103) are the only markets above 100; Singapore (96) and the Netherlands (90) follow closely. Sustained adoption co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye